The latest database from CGT Catapult shows that there were 27 new or initiated trials in 2024, compared with 13 in 2023.
The number of ongoing advanced therapy clinical trials in the UK reached 187 last year, an increase of 7% compared to 2023. This includes a significant increase of 70% in the number of Phase I trials, which grew from 24 to 41.
The UK remains an attractive destination for clinical trials, having representation in 9.5% of all global trials and almost 50% of all European trials in 2024.
The annual database released by the CGT Catapult also shows that there were 27 new or initiated trials in 2024, compared with 13 in 2023, indicating a growing pipeline of products. Similar to 2023, the majority of advanced therapy medicinal product (ATMP) clinical trials in 2024 were in gene therapies.
These are important in two regards. “They provide a clear indication of the attractiveness of the UK for advanced therapy product development, and they create the skills, capabilities and environment that mean that patients can access these life changing drugs more quickly and easily,” says Matthew Durdy, chief executive of the CGT Catapult.
CGT Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies. It helps companies, researchers and innovators accelerate their cell and gene therapy to market throughout development, manufacturing and clinical adoption.
